Trending NewsTrending NewsNASDAQ:CRBU Caribou Biosciences (CRBU) Stock Price, News & Analysis $0.46 -0.02 (-4.36%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$0.46 +0.00 (+1.04%) As of 10/9/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Caribou Biosciences Stock (NASDAQ:CRBU) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Caribou Biosciences alerts:Sign Up Key Stats Today's Range$0.44▼$0.5250-Day Range$0.46▼$1.7652-Week Range$0.44▼$3.54Volume9.68 million shsAverage Volume4.13 million shsMarket Capitalization$49.34 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingHold Company Overview Caribou Biosciences, Inc. is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient. Caribou’s research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA. Its therapies are intended to enhance the persistence, activity and availability of engineered immune cells by making targeted genetic changes during cell development. These candidates remain investigational and have not been approved for general commercial use. Founded in 2011 and headquartered in Berkeley, California, Caribou was built around CRISPR technology co-developed by a group that included Nobel Prize-winning scientist Jennifer Doudna. Rachel Haurwitz, Ph.D., a co-founder of the company, has served as its president and chief executive officer. Caribou conducts its biotechnology development primarily in the United States and works with research, clinical and industry partners to advance its cell-therapy programs.AI Generated. May Contain Errors. Read More Caribou Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreCRBU MarketRank™: Caribou Biosciences scored higher than 60% of companies evaluated by MarketBeat, and ranked 336th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingCaribou Biosciences has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 1 strong buy rating, 2 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialCaribou Biosciences has a consensus price target of $5.50, representing about 1,095.1% upside from its current price of $0.46.Amount of Analyst CoverageCaribou Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Caribou Biosciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Caribou Biosciences are expected to grow in the coming year, from ($1.07) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Caribou Biosciences is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Caribou Biosciences is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCaribou Biosciences has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Caribou Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.17% of the float of Caribou Biosciences has been sold short.Short Interest Ratio / Days to CoverCaribou Biosciences has a short interest ratio ("days to cover") of 13.09, which indicates bearish sentiment.Change versus previous monthShort interest in Caribou Biosciences has recently decreased by 0.49%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCaribou Biosciences does not currently pay a dividend.Dividend GrowthCaribou Biosciences does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.27 News SentimentCaribou Biosciences has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Caribou Biosciences this week, compared to 3 articles on an average week.Search Interest6 people have searched for CRBU on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Caribou Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Caribou Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders8.54% of the stock of Caribou Biosciences is held by insiders.Percentage Held by Institutions77.51% of the stock of Caribou Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Caribou Biosciences' insider trading history. Receive CRBU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Caribou Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRBU Stock News HeadlinesCaribou Biosciences (NASDAQ:CRBU) Stock Gets Downgrade from HC WainwrightOctober 10 at 2:38 AM | americanbankingnews.comBrookline Capital Markets Downgrades Caribou Biosciences (NASDAQ:CRBU) to HoldOctober 9 at 1:55 AM | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)HC Wainwright & Co. downgrades Caribou Biosciences to neutral from buyOctober 8 at 5:42 PM | msn.comLeerink Partners Downgrades Caribou Biosciences (NASDAQ:CRBU) to Market PerformOctober 8 at 7:15 AM | americanbankingnews.comContrasting Caribou Biosciences (NASDAQ:CRBU) & TG Therapeutics (NASDAQ:TGTX)October 8 at 5:44 AM | americanbankingnews.comRBC Downgrades Caribou Biosciences to Sector Perform From Outperform, Cuts Price Target to $1 From $10, Keeps Speculative RiskOctober 7 at 3:19 PM | marketscreener.comMCaribou Biosciences To Halt Two CAR-T Programs, Cut Workforce; Shares PlungeOctober 7 at 3:19 PM | rttnews.comSee More Headlines CRBU Stock Analysis - Frequently Asked Questions How have CRBU shares performed this year? Caribou Biosciences' stock was trading at $1.59 at the beginning of the year. Since then, CRBU shares have decreased by 71.1% and is now trading at $0.4602. How were Caribou Biosciences' earnings last quarter? Caribou Biosciences, Inc. (NASDAQ:CRBU) released its quarterly earnings data on Thursday, August, 13th. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.08. The business earned $1.50 million during the quarter, compared to analysts' expectations of $2.28 million. Caribou Biosciences had a negative trailing twelve-month return on equity of 89.11% and a negative net margin of 1,030.42%. When did Caribou Biosciences IPO? Caribou Biosciences (CRBU) raised $285 million in an initial public offering on Wednesday, July 21st 2021. The company issued 19,000,000 shares at a price of $14.00-$16.00 per share. Who are Caribou Biosciences' major shareholders? Caribou Biosciences' top institutional investors include Green Alpha Advisors LLC (0.51%). Insiders that own company stock include Rachel E Haurwitz, Barbara G Mcclung, Ruhi Ahmad Khan, Timothy P Kelly, Tina M Albertson and Sriram Ryali. View institutional ownership trends. How do I buy shares of Caribou Biosciences? Shares of CRBU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Caribou Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Caribou Biosciences investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/13/2026Today10/10/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 4 days ago, CRBU's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CRBU CIK1619856 Webcariboubio.com Phone510-982-6030FaxN/AEmployees97Year Founded2012Price Target and Rating Average Price Target for Caribou Biosciences$5.50 High Price Target$11.00 Low Price Target$1.00 Potential Upside/Downside+1,095.1%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$148.12 million Net Margins-1,030.42% Pretax Margin-1,035.90% Return on Equity-89.11% Return on Assets-62.47% Debt Debt-to-Equity RatioN/A Current Ratio6.49 Quick Ratio6.49 Sales & Book Value Annual Sales$11.16 million Price / Sales4.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book0.35Miscellaneous Outstanding Shares107,210,000Free Float98,052,000Market Cap$49.34 million OptionableOptionable Beta2.31 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:CRBU) was last updated on 10/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
